Transcode Therapeutics (NASDAQ: RNAZ) stock up 80% - Volatile on stock issue

Transcode Therapeutics (NASDAQ: RNAZ) stock is up 80% premarket this morning. RNAZ stock is also down around 50% from its peak a few days back. So, it’s fair to say that there’s a certain amount of volatility here. That’s also fair enough for the company has filed to issue more stock but as yet we don’t seem to know the price they’re going to try and issue at. That’s what also contains a certain danger for us. Any increase in the RNAZ stock price here will increase the likely issuance price - making it more expensive for us to buy in even as - because of - it’s less dilutive to current shareholders. 

As to what’s done at Transcode: “TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.” It’s in that high risk business of pharma development. Something that takes years, often ends in failure and has to be funded by shareholder capital along the way. All of which is fine as long as we grasp that before we play in the sector.

r

Transcode Therapeutics stock price from Google Finance

We can see that recent price peak and the decline from there. This is likely why: “We are offering 8,700,000 shares of our common stock on a firm commitment basis.

Our common stock is listed on the Nasdaq Capital Market under the symbol “RNAZ.” The last reported sale price of our common stock on the Nasdaq Capital Market on September 7, 2023 was $1.15 per share. The final public offering price will be determined through negotiation between us and the underwriter; the recent market price used throughout this prospectus may not be indicative of the actual offering price.” As we say, development has to be paid for with shareholder capital. So stock issuance isn’t a grand surprise. 

We should also say that issuing near 9 million shares at something around a $1 each is very ambitious for a company with a current market capitalisation of around $1 million. So much so that we rather think that one of those numbers must be wrong but those are what are reported. 

If we were more cynical than we are we’d be ascribing the current rise, today’s 80%, to someone trying to get the stock price up so as to make this new issue less dilutive. Given that we’re not that cynical we’ll not say so. But we would suggest that if Transcode is something anyone wants to buy into then it’s almost certainly better to await the pricing of the new issue and then make a decision.